
CLAIMS

1. A pharmaceutical combination product comprising


a) a compound of the formula:



Compound (I)

wherein X^- is a pharmaceutically acceptable anion; and

b) a compound of the formula:



Compound (II)

or a pharmaceutically acceptable salt thereof, said product is formulated to be suitable for a once-daily administration.

2. A product according to claim 1 wherein for Compound (I) the pharmaceutically acceptable anion is selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.

3. A product according to claim 1 or 2 wherein Compound (I) is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide.

4. A product according to any one of claims 1 to 3 wherein Compound (II) is 4-{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate.

5. A pharmaceutical combination product according to any one of claims 1 to 4 comprising:
a) 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide as Compound I; and
b). 4-{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate as Compound II.

6. A product according to any one of claims 1 to 5, wherein Compound (I) and Compound (II) are presented in a form adapted for separate, sequential or simultaneous administration.

7. A product according to any one of claims 1 to 6, in a form suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a unit-dose dry powder inhaler, a pre-metered multi-dose dry powder inhaler, a nasal inhaler or a pressurised metered dose inhaler.

8. A product according to claim 7, wherein Compound (I) and Compound (II) are presented in separate dry powder compositions or an admixed dry powder composition.

9. A product according to claim 8, wherein each composition contains a carrier, which is lactose.

10. A product according to claim 8 or 9, wherein each composition contains a ternary agent.

11. A product according to claim 10, wherein the ternary agent is magnesium stearate, present in an amount of about 0.6%w/w in the composition of Compound (I), and/or an amount of about 1.0%w/w in a composition of Compound (II).

12. A product according to any one of claims 8 to 11, wherein said separate compositions are in unit dose form, and further wherein the unit dose form is a capsule, cartridge or blister pack.

13. A product according to any one of claims 1 to 12, wherein Compound (I) is present in an amount of 125mcg/dose (of the free cation) or 62.5mcg/dose (of the free cation).

14. A product according to any one of claims 1 to 13, wherein Compound (II) is present in an amount of 25mcg/dose (of the free base).

15. A product according to any one of claims 1 to 14, further comprising 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester (fluticasone furoate).

16. A product according to claim 15, wherein 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid *S*-fluoromethyl ester (fluticasone furoate) is present in an amount of 100mcg/dose.

17. A dry powder inhaler containing a product as defined in any one of claims 1 to 16.

18. A product according to any one of claims 1 to 16, for use in the treatment of inflammatory or respiratory tract diseases selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis, small airways disease, bronchiectasis and cystic fibrosis.

19. A product for use according to claim 18, wherein the disease is chronic obstructive lung disease.

20. A product for use according to claim 18 or 19, wherein the product is for a once-a-day administration.

21. Use of the product according to any one of claims 1 to 16, in the manufacture of a medicament for the treatment of inflammatory or respiratory tract diseases selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis, small airways disease, bronchiectasis and cystic fibrosis.

22. The use according to claim 21, wherein the disease is chronic obstructive lung disease.

23. The use according to claim 21 or 22, wherein the product is to be administered once a day.